StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics cash

Cash and short-term investments held at the end of each period.

TScan Therapeutics's cash was $100.16M at Jun 30, 2026. For fiscal 2025 it was $152.41M, down 48.4% from the year before. The highest annual figure on record is $295.14M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$152.41M-48.4%
FY2024Dec 31, 2024$295.14M+49.8%
FY2023Dec 31, 2023$197.08M+57.6%
FY2022Dec 31, 2022$125.06M-24.9%
FY2021Dec 31, 2021$166.44M+370.3%
FY2020Dec 31, 2020$35.39M-16.5%
FY2019Dec 31, 2019$42.36M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$100.16M-54.1%
Q1 FY2026Mar 31, 2026$128.06M-49.1%
Q4 FY2025Dec 31, 2025$152.41M-48.4%
Q3 FY2025Sep 30, 2025$184.45M-32.0%
Q2 FY2025Jun 30, 2025$218.05M-26.8%
Q1 FY2025Mar 31, 2025$251.69M+54.6%
Q4 FY2024Dec 31, 2024$295.14M+49.8%
Q3 FY2024Sep 30, 2024$271.12M+25.9%
Q2 FY2024Jun 30, 2024$297.68M+42.5%
Q1 FY2024Mar 31, 2024$162.78M+70.3%
Q4 FY2023Dec 31, 2023$197.08M+57.6%
Q3 FY2023Sep 30, 2023$215.42M+56.9%
Q2 FY2023Jun 30, 2023$208.84M+66.3%
Q1 FY2023Mar 31, 2023$95.61M-32.1%
Q4 FY2022Dec 31, 2022$125.06M-24.9%
Q3 FY2022Sep 30, 2022$137.31M-24.7%
Q2 FY2022Jun 30, 2022$125.60M+18.3%
Q1 FY2022Mar 31, 2022$140.84M+15.9%
Q4 FY2021Dec 31, 2021$166.44M+370.3%
Q3 FY2021Sep 30, 2021$182.31M+313.6%
Q2 FY2021Jun 30, 2021$106.20M+107.4%
Q1 FY2021Mar 31, 2021$121.50M+186.8%
Q4 FY2020Dec 31, 2020$35.39M–
Q3 FY2020Sep 30, 2020$44.08M–
Q2 FY2020Jun 30, 2020$51.21M–
Q4 FY2019Dec 31, 2019$42.36M–

More TScan Therapeutics figures

See a number that looks wrong?